Talphera (TLPH) Share-based Compensation (2010 - 2026)
Talphera's (TLPH) quarterly Share-based Compensation came in at $214000.0 in Q1 2026, up 9.18% year-on-year from $196000.0 in Q1 2025, and up 147.56% quarter-over-quarter from -$450000.0 in Q4 2025.
Talphera (TLPH) Share-based Compensation (2010 - 2026) Analysis & Trends
Talphera's Share-based Compensation history runs 17 years deep, the most recent figure standing at $214000.0 for Q1 2026.
- On a quarterly basis, Share-based Compensation rose 9.18% year-over-year to $214000.0 in Q1 2026; TTM through Mar 2026 was $112000.0, a 761.54% increase from a year earlier, with the FY2025 full-year figure at $1.0 million, up 740.34% from the prior year.
- Share-based Compensation climbed to $214000.0 in Q1 2026 per TLPH's latest filing, from -$450000.0 in the prior quarter.
- Across five years, Share-based Compensation topped out at $2.8 million in Q4 2022 and bottomed at -$640000.0 in Q4 2024.
- The 5-year median for Share-based Compensation is $302000.0 (2024), against an average of $433882.4.
- Across the five-year window, Share-based Compensation soared 881.03% in 2023 and tumbled 305.79% in 2024, its largest moves.
- Year by year, Share-based Compensation stood at $2.8 million in 2022, then plunged by 88.91% to $311000.0 in 2023, then tumbled by 305.79% to -$640000.0 in 2024, then gained by 29.69% to -$450000.0 in 2025, then surged by 147.56% to $214000.0 in 2026.
- Per Business Quant, the three latest TLPH Share-based Compensation figures stand at $214000.0 (Q1 2026), -$450000.0 (Q4 2025), and $152000.0 (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 43.00 Mn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 25.00 Mn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 125.69 Mn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 58.30 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 56.50 Mn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 55.70 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 21.00 Mn |
| 10 | Talphera | 47.31 Mn | 9.48 Mn | - | 214,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 214,000.00 |
| Mar 31, 2026 | 214,000.00 |
| Dec 31, 2025 | -450,000.00 |
| Dec 31, 2025 | -450,000.00 |
| Sep 30, 2025 | 152,000.00 |
| Sep 30, 2025 | 152,000.00 |
| Jun 30, 2025 | 1.10 Mn |
| Jun 30, 2025 | 1.10 Mn |
| Mar 31, 2025 | 196,000.00 |
| Mar 31, 2025 | 196,000.00 |
| Dec 31, 2024 | -640,000.00 |
| Dec 31, 2024 | -640,000.00 |
| Sep 30, 2024 | 234,000.00 |
| Sep 30, 2024 | 234,000.00 |
| Jun 30, 2024 | 223,000.00 |
| Jun 30, 2024 | 223,000.00 |
| Mar 31, 2024 | 302,000.00 |
| Mar 31, 2024 | 302,000.00 |
| Dec 31, 2023 | 311,000.00 |
| Dec 31, 2023 | 311,000.00 |